GEFTIGET

Description

Gefitinib belongs to a new class of anti cancer drugs called tyrosine-kinase inhibitors which preferentially targets cancer cells unlike the older cancer chemotherapeutic drugs. Gefitinib has shown excellent results in a sub-group of lung cancer patients with EGFR mutation.

Indication:

• As monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from gefitinib